MannKind Reports Q1 Net Loss Amid Soaring Expenses, Despite Revenue Growth
MNKD sits 48% above its 52-week low of $2.23 on elevated volume (6.0× avg).
Summary
MannKind reported a net loss of $16.6 million for Q1 2026, a sharp decline from a profit in the prior year, despite a 15% increase in total revenues driven by new product sales and royalties.
Key Events · Earnings and Guidance · MNKD
-
Swing to Net Loss
The company reported a net loss of $16.6 million for the first quarter of 2026, a significant reversal from a net income of $13.2 million in the same period last year.
-
Revenue Growth Driven by Acquisitions and Royalties
Total revenues increased by 15% to $90.2 million, primarily due to $15.5 million in new Furoscix sales following the scPharma acquisition in October 2025 and a 9% increase in Tyvaso DPI royalties.
-
Substantial Increase in Operating Expenses
Selling, General, and Administrative (SG&A) expenses surged by 116% to $54.1 million, largely attributed to Furoscix promotion and preparations for a potential pediatric launch of Afrezza. Research and Development (R&D) expenses also rose 56% to $17.2 million.
-
Debt Settlement Impacts Cash Position
MannKind settled $36.3 million in senior convertible notes using $35.5 million in cash and 569,023 shares, resulting in a $0.9 million loss on settlement. Cash and cash equivalents decreased by $22 million during the quarter.
Analysis · MNKD · Life Sciences
MannKind Corporation's first-quarter results reveal a significant shift from profitability to a net loss, primarily driven by a substantial increase in operating expenses. While revenue growth, boosted by the scPharma acquisition and Tyvaso DPI royalties, is a positive, the surge in SG&A and R&D costs raises concerns about the company's path to sustainable profitability. The cash burn and the use of a significant portion of cash for debt settlement highlight ongoing liquidity management challenges. Investors will be closely watching future quarters for signs of expense control and improved operating leverage, especially as the company invests heavily in new product launches and development programs.
At the time of this filing, MNKD was trading at $3.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.